New radiation strategy aims to outsmart aggressive brain tumors
NCT ID NCT07459101
First seen Mar 11, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study is for people with glioblastoma, a fast-growing brain cancer. It tests a new way to give radiation therapy that adapts to changes in the tumor and uses smaller treatment areas. The goal is to see if this approach can better control the cancer and improve survival compared to standard radiation. About 60 participants will be followed to measure outcomes like tumor progression, side effects, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sunnybrook Health Sciences Centre - Odette Cancer Centre
RECRUITINGToronto, Ontario, M4N3M5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.